Compare LEN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | NTRA |
|---|---|---|
| Founded | 1954 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 27.0B |
| IPO Year | N/A | 2015 |
| Metric | LEN | NTRA |
|---|---|---|
| Price | $121.38 | $237.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | $111.46 | ★ $249.53 |
| AVG Volume (30 Days) | ★ 4.2M | 1.1M |
| Earning Date | 12-16-2025 | 02-26-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.98 | N/A |
| Revenue | ★ $34,186,934,000.00 | $2,116,676,000.00 |
| Revenue This Year | $0.28 | $33.18 |
| Revenue Next Year | N/A | $16.81 |
| P/E Ratio | $15.45 | ★ N/A |
| Revenue Growth | N/A | ★ 38.17 |
| 52 Week Low | $98.42 | $125.38 |
| 52 Week High | $144.24 | $256.36 |
| Indicator | LEN | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 55.14 |
| Support Level | $102.80 | $226.12 |
| Resistance Level | $123.75 | $243.47 |
| Average True Range (ATR) | 3.30 | 8.19 |
| MACD | 2.64 | -0.52 |
| Stochastic Oscillator | 88.79 | 41.80 |
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.